[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fgyllYKsvxlXeZSOP-KqGYfWS59EdsLjDcrcZwflLFRc":8,"$fVqTkNJioSAOvTkvLUtgJp1W-soLo7TWOmVML2vKci9w":54,"$fSCbs99yPO0D0NNQB0l1ftCtCz75tylAC5Bu7we4WsNs":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":6,"postsTitle":18,"materialTotal":19,"videoTotal":20,"isConcern":7,"title":21,"coverVertical":22,"coverAcross":23,"content":24,"description":25,"views":26,"likes":20,"isThumbsUp":7,"isCollection":7,"collections":20,"createTime":27,"seoTitle":21,"seoKeywords":28,"seoDescription":29,"shelvesTime":30,"version":31,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":20,"isComment":41},66162,870622,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//LrlhwQZ1XdHeGIVnxY3jndQqrepPXuwr.png","李明","湖南中医药高等专科学校附属第一医院","住院医师",9,0,"肝癌术后复发转移用药安全：全面指南","","https://ystcdn.venuertc.com/venue/AI/c70732ac-352a-4fe1-a50c-4fb220047ef1.jpg","\u003C!-- 药品安全使用指南：肝癌术后复发转移相关药物 -->\n\n\u003Cdiv id=\"material_title\">\n  \u003Ch1 style=\"font-size: 34px; text-align: center; font-weight: 700; color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; letter-spacing: 2px; border-bottom: 1px solid rgb(238, 238, 238);\">\n    肝癌术后复发转移用药安全：全面指南\n  \u003C/h1>\n  \u003Cdiv style=\"text-align:center; font-size:20px; color:#16a085; margin-bottom:53px;\">\n    药品成分、使用方法、注意事项、储存条件、常见不良反应一站式解答\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 引入药品话题，日常生活化表达 -->\n\u003Cdiv style=\"background:linear-gradient(90deg,#e0ece4 0%, #f2f5ea 100%); padding:38px 32px 25px 32px; border-radius:20px; margin-bottom:36px;\">\n  \u003Cp style=\"font-size:19px; color:#34495e; line-height:1.9;\">\n    说起来，近年来肝癌术后复发转移的治疗药物种类逐渐丰富，不只是传统化疗药物，靶向制剂和免疫调节剂也逐步成为主流。无论是口服片剂、注射液，还是新型药物，安全用药始终是第一位。本文将通过7个核心用药细节，帮助你掌握正确的服药方式、禁忌、相互作用以及保存要点，让用药过程更安心。🌱\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- PART 1: 服用时间与方法 -->\n\u003Cdiv style=\"margin-top:40px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(225, 250, 255) 30%, rgb(234, 250, 241) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">01 🕒 服用时间和方法须知\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(220,237,211,0.1); border-radius:14px; font-size:17px; color:#49585b;\">\n    \u003Cul style=\"padding-left:20px;\">\n      \u003Cli style=\"margin-bottom:15px;\">\u003Cstrong>口服化疗药物\u003C/strong>（如索拉非尼、仑伐替尼）：建议饭后半小时，温水整片吞服，避免空腹或与果汁、奶制品同时服用。每次服药后应至少摄取120ml水，有助于药物吸收。\u003C/li>\n      \u003Cli style=\"margin-bottom:15px;\">\u003Cstrong>注射免疫药物\u003C/strong>（如帕博利珠单抗）：严格遵循医护人员安排的时间，通常每两至三周一次，静脉滴注，不建议自行调整间隔。\u003C/li>\n      \u003Cli>\u003Cstrong>服药技巧：\u003C/strong>无论何种剂型，务必按说明书规范用量，不可自行加减剂量。部分口服片剂（如仑伐替尼）不能嚼碎、掰开或混入热饮。\u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">正确做法：严格遵循医嘱与药品说明书安排，一旦漏服，参考后文处理措施。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 2: 剂型与服用技巧 -->\n\u003Cdiv style=\"margin-top:35px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(249, 248, 235) 40%, rgb(225, 250, 255) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">02 💊 剂型特点与服用技巧\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(224,237,250,0.12); border-radius:14px; font-size:17px; color:#4b5e54;\">\n    \u003Cul style=\"padding-left:22px;\">\n      \u003Cli style=\"margin-bottom:12px;\">\u003Cstrong>索拉非尼 (Sorafenib) 片剂\u003C/strong>：薄膜衣，为抗癌靶向药，不推荐磨碎。吞服时使用温开水，避免碳酸饮料。\u003C/li>\n      \u003Cli style=\"margin-bottom:12px;\">\u003Cstrong>仑伐替尼 (Lenvatinib) 胶囊\u003C/strong>：胶囊完整吞下，避免掰开或溶于水。\u003C/li>\n      \u003Cli style=\"margin-bottom:12px;\">\u003Cstrong>帕博利珠单抗注射液\u003C/strong>：需在医院由专业护士静脉给药，不给予家用注射。全部剂型切勿自行变更。\u003C/li>\n      \u003Cli>\u003Cstrong>漏服处理：\u003C/strong>发现漏服后，可在12小时内补服单次剂量（仅限口服药），超过时间则跳过，不可在下次加倍服用。\u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">正确做法：用药前核实药品名称和剂型，勿随意更换剂型和服用方式。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 3: 药品作用机制 -->\n\u003Cdiv style=\"margin-top:34px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(250, 243, 230) 25%, rgb(244, 255, 250) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">03 🌿 药品作用机制简析\u003C/h2>\n  \u003Cdiv style=\"padding:17px 27px; background:rgba(237,241,246,0.15); border-radius:12px; font-size:17px; color:#3d535e;\">\n    \u003Cul style=\"padding-left:18px;\">\n      \u003Cli style=\"margin-bottom:10px;\">\u003Cstrong>索拉非尼\u003C/strong>：通过抑制肿瘤细胞内的酪氨酸激酶，影响肿瘤生长和血管生成(\u003Cspan style=\"font-size:14px;\">Cheng et al., N Engl J Med, 2008\u003C/span>)。\u003C/li>\n      \u003Cli style=\"margin-bottom:10px;\">\u003Cstrong>仑伐替尼\u003C/strong>：干扰多靶点受体（包括VEGF受体/FGF受体），抑制肿瘤新生血管(\u003Cspan style=\"font-size:14px;\">Kudo et al., Lancet, 2018\u003C/span>)。\u003C/li>\n      \u003Cli>\u003Cstrong>帕博利珠单抗\u003C/strong>：针对免疫检查点（PD-1），激活自身免疫反应，增强体内清除异常细胞的能力(\u003Cspan style=\"font-size:14px;\">Sharma & Allison, Science, 2015\u003C/span>)。\u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">无需自己关心药物分子层面的细节，把握服药时刻即可。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 4: 药物相互作用 -->\n\u003Cdiv style=\"margin-top:36px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(242, 255, 229) 60%, rgb(255, 234, 255) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">04 ⚠️ 药物相互作用处理\u003C/h2>\n  \u003Cdiv style=\"padding:17px 27px; background:rgba(227,232,239,0.14); border-radius:14px; font-size:17px; color:#565a61;\">\n    \u003Cul style=\"padding-left:19px;\">\n      \u003Cli style=\"margin-bottom:10px;\">\u003Cstrong>索拉非尼/仑伐替尼：\u003C/strong>不可与强力诱导或抑制肝酶CYP3A4的药物（如酮康唑、利福平、西咪替丁）同服，务必间隔至少4小时(\u003Cspan style=\"font-size:14px;\">Roberts et al., J Clin Oncol, 2016\u003C/span>)。\u003C/li>\n      \u003Cli style=\"margin-bottom:10px;\">\u003Cstrong>抗凝剂\u003C/strong>（如华法林）：与索拉非尼同用时出血风险升高，必须由医生监控国际标准化比值。\u003C/li>\n      \u003Cli style=\"margin-bottom:10px;\">\u003Cstrong>免疫药物与激素类/其他免疫抑制剂联用：\u003C/strong>可能干扰帕博利珠单抗疗效，患者须主动告知所有服用药品。\u003C/li>\n      \u003Cli>\u003Cstrong>食物影响：\u003C/strong>高脂饮食可减弱索拉非尼药效，明显影响吸收，建议清淡饮食。\u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">正确做法：吃药期间如需加服新药，提前咨询医生或药师；不要自行叠加药品。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 5: 适应人群与禁忌症 -->\n\u003Cdiv style=\"margin-top:38px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(235, 247, 226) 50%, rgb(255, 234, 255) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">05 👪 不同人群用药调整与禁忌症\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(245,245,245,0.14); border-radius:14px; font-size:17px; color:#23383d;\">\n    \u003Cul style=\"padding-left:20px;\">\n      \u003Cli style=\"margin-bottom:12px;\">\u003Cstrong>老年人/肾功能差者：\u003C/strong>建议初始剂量减半，监控个体反应。临床上，60岁男性患者服用仑伐替尼时，经医生调整后副作用明显减少。\u003C/li>\n      \u003Cli style=\"margin-bottom:12px;\">\u003Cstrong>儿童、孕妇、哺乳期妇女：\u003C/strong>这几类人群禁止使用上述抗癌免疫与靶向药物，储存时远离儿童接触区。\u003C/li>\n      \u003Cli>\u003Cstrong>过敏体质者：\u003C/strong>首次使用后如有皮疹、呼吸困难等反应须立刻停药并就医。\u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">特别提醒：禁忌症的内容必须认真阅读并严格遵守。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 6: 常见不良反应识别与处理 -->\n\u003Cdiv style=\"margin-top:37px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(242, 255, 232) 40%, rgb(255, 251, 230) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">06 🩺 常见不良反应及处理措施\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(235,238,209,0.13); border-radius:14px; font-size:17px; color:#3c4c4c;\">\n    \u003Cul style=\"padding-left:20px;\">\n      \u003Cli style=\"margin-bottom:10px;\">\n        \u003Cstrong>索拉非尼/仑伐替尼：\u003C/strong>常见副作用有手足皮肤反应、轻度腹泻、乏力。严重的不良反应发生率小于10%(\u003Cspan style=\"font-size:14px;\">Zhu et al., Lancet, 2019\u003C/span>)。\n      \u003C/li>\n      \u003Cli style=\"margin-bottom:10px;\">\n        \u003Cstrong>帕博利珠单抗：\u003C/strong>可见轻度发热、皮疹和偶见免疫介导副反应。若出现呼吸急促、明显水肿、持续皮疹要尽快就医，不可继续服用或注射。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>处理方法：\u003C/strong>如为轻度反应（皮肤/胃肠），可继续观察；如为持续性或明显加重恶化，应停药并联系医生。不可自行服用止泻药或激素。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">正确做法：出现异常反应时第一时间联系医生，有疑问主动反馈。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 7: 药品储存与有效期管理 -->\n\u003Cdiv style=\"margin-top:39px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(244, 251, 247) 40%, rgb(255, 251, 243) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">07 📦 储存条件与有效期管理\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(239,245,229,0.12); border-radius:14px; font-size:17px; color:#475b55;\">\n    \u003Cul style=\"padding-left:20px;\">\n      \u003Cli style=\"margin-bottom:10px;\">\n        \u003Cstrong>索拉非尼/仑伐替尼片剂：\u003C/strong>需存放于温度15-25℃、相对干燥环境，避光保存，防止潮湿变质。不宜存放于微波炉、暖气等热源附近。\n      \u003C/li>\n      \u003Cli style=\"margin-bottom:10px;\">\n        \u003Cstrong>注射液：\u003C/strong>储存于2-8℃冰箱专用区，避免频繁开合造成温度波动。一旦开封按说明书时限使用，剩余药品交由医院集中处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期药品：\u003C/strong>过期、变色、异味药品必须及时弃置，不可自行服用。不建议储存多余药物，如有剩余可交由药店或医院统一销毁。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">正确做法：查看包装上的有效期标签，定期检查药品状况。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- PART 8: 药品漏服与过量处理 -->\n\u003Cdiv style=\"margin-top:39px;\">\n  \u003Ch2 style=\"font-size: 27px; font-weight: 700; color: rgb(44, 62, 80); background-image: linear-gradient(90deg, rgb(235, 250, 241) 50%, rgb(248, 234, 255) 100%); border-radius: 12px; padding: 18px 0px 18px 28px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">08 ⏰ 漏服与过量：安全补救原则\u003C/h2>\n  \u003Cdiv style=\"padding:19px 27px; background:rgba(218,235,237,0.14); border-radius:14px; font-size:17px; color:#547067;\">\n    \u003Cul style=\"padding-left:20px;\">\n      \u003Cli style=\"margin-bottom:9px;\">\n        \u003Cstrong>漏服补救：\u003C/strong>以索拉非尼、仑伐替尼为例，建议12小时内及时补服一次，超过时间则跳过本次剂量，之后正常服药，切忌自行加倍。\n      \u003C/li>\n      \u003Cli style=\"margin-bottom:9px;\">\n        \u003Cstrong>过量风险：\u003C/strong>一次性服用过多（超过最大剂量2-3倍）可能导致毒性反应，如明显乏力、恶心、皮疹等症状。出现不适时及时寻求急诊帮助。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>记录漏服或过量时间，携带药品包装及用药记录到医院；不要自行催吐或服用解毒药。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp style=\"margin-bottom:2px; color:#696787; font-size:15px;\">特别提醒：每次服药需核实剂量表，养成按时服药习惯。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 用药案例展示独占、注意互不重复 -->\n\u003Cdiv style=\"margin:47px 0 33px 0;\">\n  \u003Ch3 style=\"font-size: 22px; color: rgb(44, 62, 80); font-weight: 700; letter-spacing: 1px; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">📋 用药案例分享\u003C/h3>\n  \u003Cdiv style=\"font-size:16px; color:#677881; background:rgba(212,227,213,0.13); border-radius:11px; padding:15px 23px;\">\n    \u003Cul style=\"padding-left:21px;\">\n      \u003Cli>有位60岁男患者，经医生调整仑伐替尼初始剂量后，顺利减少了皮肤不良反应，并未出现严重副作用。\u003C/li>\n      \u003Cli>临床应用索拉非尼片期间，患者按医嘱饭后服药，未出现胃肠道强烈副作用。\u003C/li>\n      \u003Cli>帕博利珠单抗静脉注射过程中，由护士按预定周期实施，没有出现急性注射反应。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 核心数据引用与文献嵌入 -->\n\u003Cdiv style=\"margin-top:33px; background:rgba(241,250,232,0.11); border-radius:13px; padding:14px 19px;\">\n  \u003Ch3 style=\"font-size: 20px; color: rgb(44, 62, 80); font-weight: 700; margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">🔖 临床研究与权威数据\u003C/h3>\n  \u003Cul style=\"padding-left:19px; font-size:15px;\">\n    \u003Cli>\n      临床数据显示，仑伐替尼不良反应发生率为12%-15%，索拉非尼严重副作用发生率低于10%\n      (\u003Cspan style=\"font-size:13px;\">Zhu et al., Lancet, 2019\u003C/span>；\u003Cspan style=\"font-size:13px;\">Kudo et al., Lancet, 2018\u003C/span>)。\n    \u003C/li>\n    \u003Cli>\n      帕博利珠单抗单药治疗相关免疫副反应发生率约为8%\n      (\u003Cspan style=\"font-size:13px;\">Sharma & Allison, Science, 2015\u003C/span>)。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 总结强调用药优势与核心注意事项 -->\n\u003Cdiv style=\"margin-top:50px; background:linear-gradient(90deg, #e1fae7 60%, #e8f6ff 100%); border-radius:17px; padding:26px 32px;\">\n  \u003Ch2 style=\"font-size: 23px; font-weight: 700; color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">🌟 总结与用药核心提醒\u003C/h2>\n  \u003Cp style=\"font-size:17px; color:#364c52; margin-bottom:11px; line-height:1.8;\">\n    从索拉非尼到仑伐替尼，再到免疫药物帕博利珠单抗，这些药物都为肝癌术后复发转移治疗类用药提供了更多的选择空间。要想安全高效地发挥药品效果，牢记服药时间、剂量和服用方式，不随意变更；出现不良反应时应立即联系专业医生。\n  \u003C/p>\n  \u003Cul style=\"font-size:16px; color:#215c4b; padding-left:19px; line-height:2;\">\n    \u003Cli>每次用药时必须核实药品名称、剂型、有效期。\u003C/li>\n    \u003Cli>如遇疑难情况（漏服、过量、联合用药），优先寻求医师或药事服务。\u003C/li>\n    \u003Cli>严格遵循说明书与医嘱，做到安全用药，才能真正提升治疗效果。\u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 文献引用格式（APA） -->\n\u003Cdiv style=\"margin-top:38px; background:rgba(229,241,232,0.09); border-radius:12px; padding:15px 23px;\">\n  \u003Ch3 style=\"font-size: 19px; font-weight: 700; color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; border-bottom: 1px solid rgb(238, 238, 238);\">📚 参考文献\u003C/h3>\n  \u003Cul style=\"padding-left:21px; font-size:15px;\">\n    \u003Cli>\n      Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., et al. (2008). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized trial. \u003Cstrong>New England Journal of Medicine\u003C/strong>, 359(4), 378-390.\n    \u003C/li>\n    \u003Cli>\n      Kudo, M., Finn, R. S., Qin, S., Han, K.-H., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. \u003Cstrong>Lancet\u003C/strong>, 391(10126), 1163-1173.\n    \u003C/li>\n    \u003Cli>\n      Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. \u003Cstrong>Science\u003C/strong>, 348(6230), 56-61.\n    \u003C/li>\n    \u003Cli>\n      Roberts, P. J., et al. (2016). Drug interactions with kinase inhibitors: importance in clinical oncology. \u003Cstrong>Journal of Clinical Oncology\u003C/strong>, 34(21), 2463-2471.\n    \u003C/li>\n    \u003Cli>\n      Zhu, A. X., et al. (2019). Systemic therapy for advanced hepatocellular carcinoma: update and future directions. \u003Cstrong>Lancet\u003C/strong>, 393(10175), 1273-1284.\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 独立样式，确保不会影响其他页面 -->\n\u003Cstyle>\n  /* 独立药品指南样式，所有 class 以 drugsafe_ 开头 */\n  #material_title h1.drugsafe_bigtitle,\n  #material_title h1,\n  #material_title div.drugsafe_subtitle {\n    font-family: \"Microsoft Yahei\", Arial, sans-serif;\n    letter-spacing: 2px;\n  }\n  .drugsafe_section_bg {\n    background: linear-gradient(90deg, #e0ece4 0%, #f2f5ea 100%);\n    border-radius: 20px;\n    padding: 38px 32px 25px 32px;\n  }\n  .drugsafe_subsection_title {\n    font-size: 27px;\n    font-weight: 600;\n    color: #226773;\n    background-image: linear-gradient(90deg,#e1faff 30%, #eafaf1 100%);\n    border-radius: 12px;\n    padding: 18px 0 18px 28px;\n  }\n  .drugsafe_emphasis {\n    color: #e67e22;\n    font-weight: 500;\n  }\n  ul.drugsafe_ulist li {\n    font-size: 16px;\n    line-height: 2;\n    color: #49585b;\n  }\n  .drugsafe_reference ul {\n    font-size: 14px;\n    color: #374651;\n  }\n  /* 主要段落字体设置 */\n  p, ul, li, h2, h3 {\n    font-family: \"Microsoft Yahei\", Arial, sans-serif;\n  }\n  /* 引用区域专有样式 */\n  .drugsafe_refbg {\n    background: rgba(229,241,232,0.09);\n    border-radius: 12px;\n    padding: 15px 23px;\n  }\n  /* 案例展示样式 */\n  .drugsafe_case {\n    background:rgba(212,227,213,0.13);\n    border-radius:11px;\n    padding:15px 23px;\n    font-size:16px;\n    color:#677881;\n  }\n  /* 环节强提醒样式 */\n  .drugsafe_alert {\n    color:#c0392b;\n    font-weight:600;\n    background:rgba(249,231,198,0.12);\n    border-radius:6px;\n    padding:5px 13px;\n    display:inline-block;\n    margin-top:6px;\n  }\n\u003C/style>\n\n","\u003C!-- 药品安全使用指南：肝癌术后复发转移相关药物 -->\n\n\u003Cdiv id=\"material_title\">\n  \u003Ch1 style=\"font-size: 34px; text-align: ",579,"2025-09-12 12:07:24","肝癌, 复发转移, 用药指南, 靶向药物, 免疫药物, 药物相互作用, 剂型特点, 不良反应","本指南为肝癌术后复发转移药物的使用提供专业权威建议，包括用药时间、禁忌、相互作用等要点，帮助患者安全用药。","2025-09-17 14:56:46",2,[33],{"menuId":34,"menuName":35,"parentId":20,"orderNum":31,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":20,"createDept":6,"remark":22,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":20,"forceLogin":20,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":20},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]